Trials / Completed
CompletedNCT03990519
A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants
A Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-26366821 | Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC). |
| DRUG | Placebo | Participants will receive sodium chloride injection as placebo on Day 1. |
Timeline
- Start date
- 2019-06-24
- Primary completion
- 2020-02-19
- Completion
- 2020-02-19
- First posted
- 2019-06-19
- Last updated
- 2025-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03990519. Inclusion in this directory is not an endorsement.